StockMarketWire.com - PureTech Health said founded entity Gelesis would deliver oral and poster presentations displaying efficacy data for a weight loss treatment at the European and International Congress on Obesity.
Adults within a subgroup treated with Plenity, on average, lost 13.5% of their total body weight during the trial, with the rate of weight loss tapering as participants approached a healthy body mass index.
The overall safety and tolerability profile within the group was no different from placebo.
At 1:11pm: [LON:PRTC] Puretech Health PLC share price was +2.5p at 276.5p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.